by David Cassak
Eugene Kleiner, founder of the powerhouse venture capital firm, Kleiner Perkins, and one of the fathers of venture capital, once...
Endosense: Facing Technology and Financing Challenges in AF
Endosense is beginning to establish itself in the tough market of atrial fibrillation with a catheter that stresses an attribute that no one has featured yet: force sensing in delivering energy. Proving the clinical value of force-sensing will be difficult enough, but Endosense faced an even greater challenge in 2009 when its long-time backer, 3i, decided it wanted to exit device venture investing and divest its stake in the company.
More from Business Strategy
More from In Vivo
• By
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
• By
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
• By
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.